← Every company
Halozyme Therapeutics Inc Insider Trading
Every director, officer and 10% holder of Halozyme Therapeutics Inc has to report each trade in its stock within two business days of making it. This is those filings.
HALO on carbonthat →Insiders filing
7
71 reported lines
Open-market buys
0
Open-market sales
40
$22.4M
Net
$22.4M
sold more
Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Helen TorleyPRESIDENT AND CEO2026-10-084.8K shat $108.18 | Sale10b5-1 plan | $520.3K |
| Helen TorleyPRESIDENT AND CEO2026-10-083.1K shat $108.91 | Sale10b5-1 plan | $336.5K |
| Helen TorleyPRESIDENT AND CEO2026-10-0811.9K shat $110.00 | Sale10b5-1 plan | $1.3M |
| Helen TorleyPRESIDENT AND CEO2026-10-08200 shat $110.51 | Sale10b5-1 plan | $22.1K |
| Helen TorleyPRESIDENT AND CEO2026-10-078.6K shat $111.03 | Sale10b5-1 plan | $954.9K |
| Helen TorleyPRESIDENT AND CEO2026-10-0710.3K shat $111.84 | Sale10b5-1 plan | $1.2M |
| Helen TorleyPRESIDENT AND CEO2026-10-07900 shat $112.78 | Sale10b5-1 plan | $101.5K |
| Helen TorleyPRESIDENT AND CEO2026-10-07200 shat $113.69 | Sale10b5-1 plan | $22.7K |
| Helen TorleyPRESIDENT AND CEO2026-10-062.3K shat $107.90 | Sale10b5-1 plan | $248.2K |
| Helen TorleyPRESIDENT AND CEO2026-10-066K shat $109.33 | Sale10b5-1 plan | $656K |
| Helen TorleyPRESIDENT AND CEO2026-10-069.9K shat $109.89 | Sale10b5-1 plan | $1.1M |
| Helen TorleyPRESIDENT AND CEO2026-10-061.8K shat $110.81 | Sale10b5-1 plan | $197.2K |
| Matthew L. PosardDirector2026-09-163.1K shat $106.13 | Sale10b5-1 plan | $329K |
| Matthew L. PosardDirector2026-09-163K shat $106.83 | Sale10b5-1 plan | $320.5K |
| Matthew L. PosardDirector2026-09-168.9K shat $108.04 | Sale10b5-1 plan | $961.1K |
| Matthew L. PosardDirector2026-09-164K shat $108.99 | Sale10b5-1 plan | $436K |
| Helen TorleyPRESIDENT AND CEO2026-09-1115.5K shat $107.15 | Sale10b5-1 plan | $1.7M |
| Helen TorleyPRESIDENT AND CEO2026-09-114.5K shat $107.55 | Sale10b5-1 plan | $484.8K |
| Helen TorleyPRESIDENT AND CEO2026-09-1014.6K shat $107.01 | Sale10b5-1 plan | $1.6M |
| Helen TorleyPRESIDENT AND CEO2026-09-105.4K shat $107.58 | Sale10b5-1 plan | $582.2K |
| Helen TorleyPRESIDENT AND CEO2026-09-0913.3K shat $107.22 | Sale10b5-1 plan | $1.4M |
| Helen TorleyPRESIDENT AND CEO2026-09-096.6K shat $107.82 | Sale10b5-1 plan | $711.2K |
| Helen TorleyPRESIDENT AND CEO2026-09-09100 shat $108.67 | Sale10b5-1 plan | $10.9K |
| Helen TorleyPRESIDENT AND CEO2026-08-197.2K shat $106.36 | Sale10b5-1 plan | $765.8K |
| Helen TorleyPRESIDENT AND CEO2026-08-199.6K shat $107.22 | Sale10b5-1 plan | $1M |
| Helen TorleyPRESIDENT AND CEO2026-08-193.2K shat $107.77 | Sale10b5-1 plan | $344.8K |
| Helen TorleyPRESIDENT AND CEO2026-08-185.7K shat $103.08 | Sale10b5-1 plan | $587.9K |
| Helen TorleyPRESIDENT AND CEO2026-08-184.9K shat $104.11 | Sale10b5-1 plan | $509.8K |
| Helen TorleyPRESIDENT AND CEO2026-08-189.4K shat $104.87 | Sale10b5-1 plan | $985.8K |
| Helen TorleyPRESIDENT AND CEO2026-08-17900 shat $98.96 | Sale10b5-1 plan | $89.1K |
| Helen TorleyPRESIDENT AND CEO2026-08-17500 shat $100.46 | Sale10b5-1 plan | $50.2K |
| Helen TorleyPRESIDENT AND CEO2026-08-172.1K shat $101.77 | Sale10b5-1 plan | $213.7K |
| Helen TorleyPRESIDENT AND CEO2026-08-179K shat $102.55 | Sale10b5-1 plan | $923K |
| Helen TorleyPRESIDENT AND CEO2026-08-177.5K shat $103.48 | Sale10b5-1 plan | $776.1K |
| Bernadette ConnaughtonDirector2026-08-101.6K shat $102.80 | Sale10b5-1 plan | $167.2K |
| Helen TorleyPRESIDENT AND CEO2026-07-08888 shat $79.28 | Sale10b5-1 plan | $70.4K |
| Helen TorleyPRESIDENT AND CEO2026-07-081K shat $80.19 | Sale10b5-1 plan | $83K |
| Bernadette ConnaughtonDirector2026-07-011K shat $76.40 | Sale10b5-1 plan | $76.4K |
| Bernadette ConnaughtonDirector2026-07-01625 shat $77.21 | Sale10b5-1 plan | $48.3K |
| Mahesh KrishnanDirector2026-06-297.3K shat $75.00 | Sale10b5-1 plan | $547.8K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on HALO
Company overviewEverything on HALO in one place, with the price.SEC filingsWhat HALO's 8-Ks say happened: results, departures, auditor changes.Planned salesSales HALO insiders have filed notice of.Who owns itEvery manager reporting a position in HALO.Funds holding itWhich funds and ETFs hold HALO, and how big a bet.LobbyingWhat HALO spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on HALO's account, and who they worked for.PatentsWhat HALO is filing at the patent office.
Follow Halozyme Therapeutics Inc (HALO) by email
New trades in Halozyme Therapeutics Inc (HALO) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.